ReviewInternational journal of molecular sciences2020
Roles of IL-1 in Cancer: From Tumor Progression to Resistance to Targeted Therapies.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
116 citing papers in PubMed, 2 syntheses or guidelines pooled it, 171 citations in OpenAlex.
- Comprehensive Review: Unveiling the Pro-Oncogenic Roles of IL-1ß and PD-1/PD-L1 in NSCLC Development and Targeting Their Pathways for Clinical Management.International journal of molecular sciences · 2023Pooled it
- Immune-related pan-cancer gene expression signatures of patient survival revealed by NanoString-based analyses.PloS one · 2023Pooled it
- Clinical and Immunologic Features of Primary Enteric-Type Thymic Adenocarcinomas: A Rare Variant of a Rare Cancer.JTO clinical and research reports · 2026Article
- Article
- Review
- Interleukin-1β Gene (Genes · 2026Observational
- Review
- CD70 drives cSCC growth by linking DNA damage response, inflammation, and tumor-stromal signaling.Cell death & disease · 2026Article
- IL-1-mediated inflammation promotes metastatic dissemination and resistance to EGFR-targeted therapy.NPJ precision oncology · 2026Article
- Emerging Role of the NLRP3 Inflammasome in the Onset of Oral Diseases and Its Potential as a Therapeutic Target.International journal of molecular sciences · 2026Review
- Image segmentation-based analysis reveals correlation between IL-1RA overexpression and worse survival outcomes in oral squamous cell carcinoma.Scientific reports · 2026Article
- Precision Management of Tumor-Associated Fever: From Classification to Targeted Intervention.Cancer management and research · 2026Review
- Interplay of Interleukin-1Oncology research · 2026Article
- Antagonist Binding Actively Disrupts Interleukin-1 Receptor Dynamics to Block Co-receptor Recruitment.Computational and structural biotechnology journal · 2026Article
- From signal overload to shared insight: creating and structuring scientific visuals for comprehension and dialogue.Frontiers in bioinformatics · 2026Article
- CD70 drives cSCC growth by linking DNA damage response, inflammation, and tumor-stromal signaling.Research square · 2025Article
- Elevated Interleukin-1β and Deep Tissue Cryptosporidium Infection in Colorectal Cancer: A Novel Association.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- M2 Macrophages are Major Mediators of Germline Risk of Endometriosis and Explain Pleiotropy With Comorbid Traits.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Tumor-associated macrophages in meningiomas: a novel biomarker for poor survival outperforming the benefits of T cells.Acta neuropathologica · 2025Article
- [PM2.5-induced M2 Polarization and IL-1α Secretion by Tumor-associated Macrophages Promotes Lung Adenocarcinoma Progression].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Article
56 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
IL-1 belongs to a family of 11 members and is one of the seven receptor-agonists with pro-inflammatory activity. Beyond its biological role as a regulator of the innate immune response, IL-1 is involved in stress and chronic inflammation, therefore it is responsible for several pathological conditions. In particular, IL-1 is known to exert a critical function in malignancies, influencing the tumor microenvironment and promoting cancer initiation and progression. Thus, it orchestrates immunosuppression recruiting pro-tumor immune cells of myeloid origin. Furthermore, new recent findings showed that this cytokine can be directly produced by tumor cells in a positive feedback loop and contributes to the failure of targeted therapy. Activation of anti-apoptotic signaling pathways and senescence are some of the mechanisms recently proposed, but the role of IL-1 in tumor cells refractory to standard therapies needs to be further investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.